Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.

Revenue
+5.86%
EPS
−95.8%
Free cash flow
−21.4%
Total debt
−9.16%

Quarter to September 2026, against a year earlier

272.44 3.88 −1.40%
Market cap
$655.6B
P/E
41.3×
Fwd P/E
40.0×
Dividend yield
1.94%
F-score
3/9
Altman Z
4.78
Beneish M
−2.26
Dividend safety
78/100

Johnson & Johnson (JNJ) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, Johnson & Johnson (JNJ) trades at a P/E ratio of 41.3×. Over the past ten years it has ranged from 9.5× (May 2024) to 380× (January 2018); the current reading is higher than 92% of that period. That is above the Drug Manufacturers General industry median of 26.6× and above the Healthcare sector median of 25.2×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 18.7× (24.87%)
FY2024 24.9× 115.20%
FY2023 11.6× (56.19%)
FY2022 26.4× 20.70%
FY2021 21.9× (23.31%)
FY2020 28.6× 10.34%
FY2019 25.9× 12.53%
FY2018 23.0× (93.56%)
FY2017 357× 1,712.12%
FY2016 19.7× 5.29%

Quarterly newest first

Period P/E ratio Change
Sep 2026 40.1× 36.30%
Jun 2026 29.4× 4.14%
Mar 2026 28.3× 50.89%
Dec 2025 18.7× 4.64%
43 more quarters

Against its own ten years

Low 9.5× High 380×
Ten-year median 23.4×
Current reading's percentile 91

P/E ratio against peers

Company P/E ratio
GILD Gilead Sciences, Inc. compare n/m
AZN AstraZeneca PLC compare 26.3×
AMGN Amgen Inc. compare 26.6×
NVS Novartis AG compare 30.9×
JNJ Johnson & Johnson 41.3×
PFE Pfizer Inc. compare 42.2×
LLY Eli Lilly and Company compare 44.5×
ABBV AbbVie Inc. compare 49.7×
MRK Merck & Co., Inc. compare 118×
Drug Manufacturers General industry median 26.6×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on JNJ